| 08.08 08:46 | dpa-AFX: Hikma Pharma Posts Strong H1 Results; Revises FY24 Guidance |
| 08.08 08:13 | dpa-AFX: *HIKMA PHARMA H1 CORE BASIC EPS 128C VS 129C LAST YEAR |
| 08.08 08:13 | dpa-AFX: *HIKMA PHARMA NOW EXPECTS FY GROUP REVENUE GROWTH OF 6% TO 8%, UP FROM 4% TO 6% |
| 08.08 08:12 | dpa-AFX: *HIKMA PHARMA : INTERIM DIVIDEND OF 32 US CENTS/SHR, UP 28% |
| 08.08 08:11 | dpa-AFX: *HIKMA PHARMA HY REVENUES $1.57 BLN VS $1.43 BLN PRIOR YEAR |
| 08.08 08:10 | dpa-AFX: *HIKMA PHARMA HY ATTRIBUTABLE PROFIT $226 MLN VS $131 MLN PRIOR YEAR |
| 08.08 08:09 | dpa-AFX: *HIKMA PHARMA HY BASIC EPS 102 US CENTS VS 59 US CENTS PRIOR YEAR |
| 08.08 08:08 | dpa-AFX: *HIKMA PHARMA UPGRADES FY GROUP REVENUE AND PROFIT GUIDANCES |
| 23.07 08:44 | dpa-AFX: Hikma Pharma Extends Recall Of Acetaminophen Injection |
| 17.06 08:16 | dpa-AFX: Hikma Pharma To Acquire Parts Of Xellia Pharma's US Finished Dosage Form Business And Assets |
| 17.06 08:07 | dpa-AFX: *HIKMA PHARMA AGREES WITH XELLIA PHARMA TO BUY PARTS OF US FINISHED DOSAGE FORM BUSINESS AND ASSETS |
| 11.06 09:50 | dpa-AFX: *CITIGROUP RAISES HIKMA PHARMACEUTICAL PRICE TARGET TO 2845 (2770) PENCE - 'BUY' |
| 03.05 08:44 | dpa-AFX: *DEUTSCHE BANK INITIATES HIKMA PHARMACEUTICAL WITH 'BUY' - TARGET 2750 PENCE |
| 25.04 09:08 | dpa-AFX: Hikma Pharma Projects 2024 Group Revenue To Grow In Range Of 4% - 6% |
| 25.04 08:28 | dpa-AFX: *HIKMA PHARMA EXPECTS 2024 GROUP REVENUE TO GROW IN RANGE OF 4% TO 6% |
| 25.04 08:21 | dpa-AFX: *HIKMA PHARMA TO PAY FINAL DIVIDEND OF 47 CENTS PER SHARE |
| 25.04 08:20 | dpa-AFX: *HIKMA PHARMA STILL EXPECTS FY CORE OPERATING PROFIT TO BE $660 MLN TO $700 MLN |
| 25.04 08:20 | dpa-AFX: *HIKMA PHARMA STILL EXPECTS FY REVENUE GROWTH TO BE 4% TO 6% |
| 29.02 07:45 | dpa-AFX: *RBC RAISES HIKMA PHARMA PRICE TARGET TO 2375 (2175) PENCE - 'SECTOR PERFORM' |
| 27.02 10:33 | dpa-AFX: *BERENBERG RAISES HIKMA PHARMACEUTICAL TARGET TO 2000 (1960) PENCE - 'HOLD' |
|
|
